A phase 2, open label, 2Arm, response rate study of talazoparib in men with DNA repair defects and metastatic castration resistant prostate cancer who previously received taxane based chemotherapy and progressed on at least 1 novel hormonal agent

  • Liow, Elizabeth (Primary Chief Investigator (PCI))
  • Kwan, Edmond (Chief Investigator (CI))

Project: Research

Project Details

Project Description

NMA Reference number: HREC/16/MonH/292
NMA SSA Reference number: SSA/17/MonH/168
Monash Health HREC Ref: 16-0000-501A
SEO Code: 920102 Cancer and Related Disorders
Effective start/end date21/04/1728/11/23